In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of…
thinkstockApril 11, 2014: Markets opened lower on Friday with the S&P 500 and the Nasdaq Composite breaking into positive territory late in the morning. Unfortunately neither index could hold the gain as…
In a new report, RBC has a list of stocks with some of the largest percentage drops and the lowest forward price-to-earnings (P/E) ratios. This may serve as shopping list for the…
Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance also allowed sellers to keep exiting the…
Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many of them.…
The recent violent sell-off has unnerved investors and given the bears the floor for the first time in a while. However, there are some positive signs that job growth and workforce participation…
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at…
ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index and immediately…
Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs generally are looking for…
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top…
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage…
After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early March, especially in Celgene, Medivation and Pharmacyclics.
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a…
Biotech and emerging pharmaceutical stocks continue to be hot, but short sellers shied away from many of them in late February. Those bucking that trend include BioMarin Pharmaceutical and Medivation.
Many bears on Wall Street say that biotech stocks are overvalued, but many trade in line with historical valuations. In a new research report, Cowen highlights upcoming catalysts that could send some…
